Since the approval of exenatide for the treatment of type 2 diabetes by the Food and Drug Administration (FDA) in 2005, research on GLP-1 RAs has become a hot topic and new analogs are constantly being introduced to the market. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.